XNAS · Healthcare · Medical - Diagnostics & Research
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.55 | -0.60 | -9.09% | $696.6M | ❌ Miss | -1.74% | -10.42% | — |
| 2026-02-26 | Q4 2025 | -0.50 | 0.36 | +172.00% | $665.5M | ✅ Beat | -0.05% | -8.77% | -15.48% |
| 2025-11-06 |
| Q3 2025 |
| -0.37 |
| -0.64 |
| -72.97% |
| $592.2M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | -0.60 | -0.74 | -23.33% | $546.6M | ❌ Miss | +14.83% | +12.31% | +19.10% |
| 2025-02-27 | Q4 2024 | -0.39 | -0.41 | -5.13% | $476.1M | ❌ Miss | -0.65% | -9.65% | -9.71% |
| 2024-11-12 | Q3 2024 | -0.57 | -0.26 | +54.39% | $439.8M | ✅ Beat | +19.13% | +19.97% | +23.19% |
| 2024-08-08 | Q2 2024 | -0.69 | -0.30 | +56.52% | $413.4M | ✅ Beat | +6.38% | +13.51% | +9.25% |
| 2024-02-28 | Q4 2023 | -0.73 | -0.65 | +10.96% | $311.1M | ✅ Beat | +12.98% | +17.86% | +21.44% |
Showing last 8 quarters.